Investors begin to take a more cautious approach to the market, risk sentiment deteriorates.
Apart from yesterday’s report by Johnson & Johnson, which paused the coronavirus vaccine tests due to unexpected side effects, everything makes us think that a cure will not be possible and the enormous increase in cases in Europe anticipates new lockdown measures.
New European restrictions
The main European countries experience a record of infections that remove the possibility of an immediate recovery of the old continent's economy, raising the level of uncertainty of investors who had largely bet on a speedy recovery thanks to a mass vaccination.
This increase in risk aversion already begins to anticipate more aggressive measures of the European Central Bank in its monetary policy and where it is first reflected is in the price of the German 10-year bond, GER10yBond, which has continued to rise for a week now, until reaching minimum yields of -0.55% not seen since the end of last July.
An extension and even an increase in the European Central Bank's asset purchase policy is already within the possibilities contemplated by the market, even more so after the latest statements by Lagarde and the decline experienced in the main high-frequency economic data that they herald a brake on the recovery of the European economy.
Euro stutters and stagnates
The euro tumbled into this negative scenario, clearly rejecting the resistance levels above the $1.1800 levels and threatening to slip back below the $1.1700 area. The strength of the dollar that acts as a safe haven helps the decline of this pair accelerate. The pair needs to confirm a daily close below $1.1700 for the downward movement to gain momentum and approach the main support zone now located between a broad $1.1620-$1.1670 band.
If this bearish scenario of the euro is confirmed, one of the most vulnerable pairs would be EUR/JPY, considered a barometer of risk sentiment since the Japanese currency also acts as a safe haven currency.
Support levels to watch are at $123.37, first, and $122.40 as the main support.
The research provided does not constitute the views of JME Financial Services (Pty)Ltd nor is it an invitation to invest with JME Financial Services (Pty)Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
As of the date the report is published, the research analyst and his/her spouse and/or relatives who are financially dependent on the research analyst, do not hold interests in the securities recommended in this report (“interest” includes direct or indirect ownership of securities).
The research analyst in not employed by JME Financial Services (Pty)Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation or particular financial needs before making a commitment to invest.
The laws of the Republic of South Africa shall govern any claim relating to or arising from the contents of the information/ research provided.
JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors